High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

NCT ID: NCT00003173

Last Updated: 2013-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-09-30
• Study Completion Date: 2003-05-31

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of high-dose thiotepa plus peripheral stem cell transplantation in treating patients with refractory solid tumors.

Detailed Description

OBJECTIVES:

• Evaluate the efficacy and toxicity of sequential cycles of high dose thiotepa with stem cell rescue and filgrastim in patients with malignancies refractory to conventional chemotherapy or for whom conventional therapy is not available.
• Evaluate the effectiveness of autologous stem cells in restoring hematopoiesis following high dose thiotepa.

OUTLINE: Patients are stratified by type of tumor (neuroectodermal CNS tumor vs non-neuroectodermal CNS tumor vs non-CNS small round blue cell tumor vs other non-CNS tumor).

Autologous stem cells are obtained prior to the administration of thiotepa. Patients who do not have peripheral blood stem cells available may undergo a bone marrow harvest instead. Thiotepa is administered as a 3 hour infusion daily for 3 consecutive days. Stem cells are reinfused approximately 72 hours following the completion of thiotepa. Filgrastim is administered the day following reinfusion of stem cells and continues until there is sufficient hematopoietic recovery.

The second course of thiotepa is administered 4 weeks following the first course in patients who have responding or stable disease, adequate stem cells, and no unacceptable toxicity. Patients receive a maximum of 2 courses.

PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study over 2 years.

Conditions

Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Retinoblastoma; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

Study Design

• Primary Study Purpose: TREATMENT

Interventions

filgrastim

Intervention Type: BIOLOGICAL

thiotepa

Intervention Type: DRUG

autologous bone marrow transplantation

Intervention Type: PROCEDURE

peripheral blood stem cell transplantation

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Malignant solid tumors
• Must have failed conventional treatment or for whom conventional therapy is not available
• Measurable disease by MRI or CT scan

• Intraocular retinoblastomas may be measured by direct visualization
• Germ cell tumors may be measured by tumor markers
• No known bone marrow involvement

PATIENT CHARACTERISTICS:

Age:

• Any age

Performance status:

• Lansky 60-100% for patients 16 and under
• Karnofsky 60-100% for patients over 16

Life expectancy:

• At least 8 weeks

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm^3
• Platelet count at least 75,000/mm^3
• If parameters not met, must have adequate stem cell yield

Hepatic:

• Bilirubin no greater than 1.5 times the upper limit of normal (ULN)
• SGOT and SGPT no greater than 2.5 times the ULN (unless liver involvement by tumor)

Renal:

• Creatinine within normal limits OR
• Creatinine clearance at least 70 mL/min

Cardiovascular:

• Fractional shortening greater than 28% on echocardiogram OR
• Ejection fraction at least 55% on RNCA prior to first cycle of thiotepa

Pulmonary:

• DLCO greater than 55% of predicted (only required if there is clinical evidence of pulmonary dysfunction)

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Prior bone marrow or peripheral blood stem cell rescue allowed

Chemotherapy:

• At least 4 weeks since prior chemotherapy if absolute neutrophil count is less than 1,000/mm^3 or platelet count is less than 75,000/mm^3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent chemotherapy except for dexamethasone for antiedema effects

Endocrine therapy:

• No concurrent use of corticosteroids used solely as antiemetics

Radiotherapy:

• At least 4 weeks since radiotherapy if absolute neutrophil count is less than 1,000/mm^3 or platelet count is less than 75,000/mm^3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent radiotherapy

Surgery:

• Not specified

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Principal Investigators

Ira Dunkel, MD

Role: STUDY_CHAIR

Memorial Sloan Kettering Cancer Center

Locations

NYU School of Medicine's Kaplan Comprehensive Cancer Center

New York, New York, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Countries

United States

Other Identifiers

P30CA008748

Identifier Type: NIH

Identifier Source: secondary_id

View Link

MSKCC-97089A3

Identifier Type: -

Identifier Source: secondary_id

NYU-97-7

Identifier Type: -

Identifier Source: secondary_id

NCI-G97-1366

Identifier Type: -

Identifier Source: secondary_id

97-089

Identifier Type: -

Identifier Source: org_study_id